These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18666459)

  • 21. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to essential medicines for children: the world health organization's global response.
    Zucker H; Rägo L
    Clin Pharmacol Ther; 2007 Nov; 82(5):503-5. PubMed ID: 17952106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global health impact: a basis for labeling and licensing campaigns?
    Hassoun N
    Dev World Bioeth; 2012 Dec; 12(3):121-34. PubMed ID: 22314005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceuticals--strategic considerations in health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S100-11. PubMed ID: 17595837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Merck: committed to access to medicines for patients throughout the world.
    Gilmartin RV
    N J Med; 2000 Nov; 97(11):27-9. PubMed ID: 11103598
    [No Abstract]   [Full Text] [Related]  

  • 26. Patents or patients? Global access to pharmaceuticals and social justice.
    de Wildt G; Khoon CC
    Med Confl Surviv; 2008; 24 Suppl 1():S52-61. PubMed ID: 18771195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to healthcare and the pharmaceutical sector.
    Leisinger KM; Schmitt KM
    Camb Q Healthc Ethics; 2011 Apr; 20(2):309-25. PubMed ID: 21435306
    [No Abstract]   [Full Text] [Related]  

  • 28. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
    Hentschel CC
    Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
    [No Abstract]   [Full Text] [Related]  

  • 29. Global policy for improvement of oral health in the 21st century--implications to oral health research of World Health Assembly 2007, World Health Organization.
    Petersen PE
    Community Dent Oral Epidemiol; 2009 Feb; 37(1):1-8. PubMed ID: 19046331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [AIDS and social justice: pharmaceutical industry and economics].
    López Guzmán J
    Cuad Bioet; 2008; 19(67):563-74. PubMed ID: 19166259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical pricing in the developing world: issues of access to medicines.
    Mrazek MF
    Expert Rev Pharmacoecon Outcomes Res; 2002 Feb; 2(1):43-50. PubMed ID: 19807429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WTO accepts rules limiting medicine exports to poor countries.
    James JS
    AIDS Treat News; 2003 Sep; (394):2-6. PubMed ID: 14669728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug assistance from drug makers.
    Hanson K
    State Legis; 2003 Jun; 29(6):22-4. PubMed ID: 12785350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A view on antimicrobial resistance in developing countries and responsible risk factors.
    Byarugaba DK
    Int J Antimicrob Agents; 2004 Aug; 24(2):105-10. PubMed ID: 15288307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the market for tuberculosis drugs in industrialized and developing nations.
    Schwalbe NR; Wells WA; Geaneotes AP; Forcellina A; Lee MG; Dicola L; Ignatius HR; Walker CL; Raafat T; Patel N
    Int J Tuberc Lung Dis; 2008 Oct; 12(10):1173-81. PubMed ID: 18812048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Removing barriers? An overview of the Canadian Access to Medicines Regime.
    Penner MD; Armstrong PG
    Health Law Can; 2008 Jun; 28(3-4):112-22. PubMed ID: 19051971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.